Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)
NCT ID: NCT00198367
Last Updated: 2019-05-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
120 participants
INTERVENTIONAL
2003-01-31
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chemoradiotherapy of NSCLC Stage IIIB
NCT00198432
Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00040794
Cisplatin and Pemetrexed With Radiation Followed by Lobectomy
NCT01373463
Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection
NCT01926483
To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
NCT02977169
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. chemotherapy: cisplatin-Gemzar (arm A) or
2. chemoradiotherapy: cisplatin-navelbine-radiotherapy (arm B) or Carboplatin-Taxol-radiotherapy (arm C).
The results obtained, in terms of feasibility and toxicity, will make it possible to select the optimal diagrams for a phase III study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cisplatin-Gemzar
Cisplatin-Gemzar
Cisplatin-Gemzar
Cisplatin-Navelbine-Radiotherapy
Cisplatin-Navelbine-Radiotherapy
Cisplatin-Navelbine-Radiotherapy
Carboplatin-Taxol-Radiotherapy
Carboplatin-Taxol-Radiotherapy
Carboplatin-Taxol-Radiotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cisplatin-Gemzar
Cisplatin-Navelbine-Radiotherapy
Carboplatin-Taxol-Radiotherapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* World Health Organization (WHO) performance status of 1 or less
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francoise Mornex, Pr
Role: PRINCIPAL_INVESTIGATOR
Hospices Civils de Lyon
Bernard Milleron, Dr
Role: PRINCIPAL_INVESTIGATOR
Intergroupe Francophone de Cancerologie Thoracique
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Lyon-Sud - Radiotherapie/Oncologie
Pierre-Bénite, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Girard N, Mornex F, Douillard JY, Bossard N, Quoix E, Beckendorf V, Grunenwald D, Amour E, Milleron B. Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial. Lung Cancer. 2010 Jul;69(1):86-93. doi: 10.1016/j.lungcan.2009.10.003. Epub 2009 Oct 29.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IFCT-0101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.